MOST PRODUCTIVE Continued significant revenue growth, intense focus on operational excellence, 6 Total Revenues of $646.2 million in the Fourth Quarter 2023 Increased 20% Q/Q Produced double-digit revenue growth and significant operating leverage in 2023, with non-GAAP diluted earnings per share increasing 36% Y/Y B:OMARIN (2) Non-GAAP Income is defined by the company as reported GAAP Net Income, excluding amortization expense, stock-based compensation expense, contingent consideration, and, in certain peri ...

BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and Chief Executive Officer Henry Fuchs - President, Worldwide Research and Development Brian Mueller - Executive Vice President and Chief Financial Officer Jeffrey Ajer - Executive Vice President and Chief Commercial Officer Greg Guyer - Executive Vice President and Chief Technical Officer, Manufacturing and Tec ...

BioMarin Pharmaceutical (BMRN) reported $646.21 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 20.2%. EPS of $0.49 for the same period compares to $0.36 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $636.71 million, representing a surprise of +1.49%. The company delivered an EPS surprise of +11.36%, with the consensus EPS estimate being $0.44.While investors scrutinize revenue and earnings changes year-over-year and how they co ...

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.36%. A quarter ago, it was expected that this rare disease biopharmaceutical would post earnings of $0.46 per share when it actually produced earnings of $0.46, delivering no surprise.Over the last four ...

Exhibit 99.1 BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024 SAN RAFAEL, Calif., February 22, 2024 – BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2023. 1 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------|-------|----------------|-------------|------------------------------------- ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 22, 2024, might help the stock move higher if these key numbers are ...

New Seven-Year Follow-Up Phase 2 Study Results Showed Durable Hemostatic Benefit for Adults with Severe Hemophilia A SAN RAFAEL, Calif., Feb. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress, Feb. 6-9, 2024. Results fro ...

BioMarin Pharmaceutical Inc. (BMRN) develops treatments for serious life-threatening medical conditions, mainly affecting children. The company’s top line is currently being driven by strong demand for its marketed products, especially new dwarfism drug, Voxzogo. Also, the recent approval of Roctavian (valoctocogene roxaparvovec, or valrox), a gene therapy for treating adults with severe hemophilia A, has opened up a key sales opportunity.BioMarin has an attractive early-stage pipeline primarily focusing on ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores a ...

The great advances and improvements in the treatment of diseases and the effectiveness of these medicines are undoubtedly due to technological progress and how biotech companies take advantage of it for their growth and development. Without the work of these companies, we would still be using very old and ineffective medicines. This new year brings with it very good opportunities to invest in companies in this sector. Here are these top biotech stocks to consider adding to your portfolio. Let’s take a look ...